Cognitive · HGF Activator

Dihexa

Dihexa is a small-molecule angiotensin IV analog studied as a hepatocyte growth factor (HGF) activator with strong neurogenic and pro-cognitive effects in animal models.

Category: Cognitive Enhancement Last updated 2026-06-19

Dihexa at a glance

Dihexa is a small-molecule angiotensin IV analog studied as a hepatocyte growth factor (HGF) activator with strong neurogenic and pro-cognitive effects in animal models. Mechanism: HGF activator (Ang IV analog). Typical route: Oral, sublingual, intranasal. FDA status: Not FDA-approved. Available through specialty compounding pharmacies and research-chemical suppliers. Human safety and efficacy data is limited; most evidence is from animal models.

Drug classHGF activator (Ang IV analog)

Half-life~10 hours

RouteOral, sublingual, intranasal

Common dosing8-45 mg/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

Dihexa potentiates hepatocyte growth factor (HGF) binding to its c-Met receptor in the brain, stimulating synaptogenesis and dendritic spine formation. Preclinical models show enhanced memory and reversal of cognitive decline in Alzheimer's mouse models.

Dosing reference

Oral: 8-45 mg per day. Sublingual or intranasal formulations are also used. Dosing in human use is not standardized; protocols vary widely.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Available through specialty compounding pharmacies and research-chemical suppliers. Human safety and efficacy data is limited; most evidence is from animal models.

U.S. telehealth providers that work with Dihexa

#1 of 3

PeterMD

71/100v3.0 six-pillar rubric

Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates Dihexa.

Read review →

#2 of 3

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates Dihexa.

Read review →

#3 of 3

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates Dihexa.

Read review →

Related cognitive enhancement peptides

Browse the full Cognitive Enhancement category →

Frequently asked questions about Dihexa

How strong is the evidence for Dihexa?

Animal-model evidence for cognitive enhancement and reversal of Alzheimer's-type deficits is robust. Human evidence is extremely limited; risk-benefit cannot be properly assessed without clinical trials.

Is Dihexa safe?

Long-term safety in humans is unknown. The compound's strong effects on growth-factor signaling raise theoretical concerns about cancer risk in long-term use; no clinical evidence either supports or refutes this concern.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing